A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Tongji Hospital
Tongji Hospital
Seoul National University Hospital
M.D. Anderson Cancer Center
Seoul National University Hospital
Seoul National University Hospital
Peking University
Seoul National University Hospital
National Health Research Institutes, Taiwan
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Fujian Medical University Union Hospital
Massachusetts General Hospital
Chinese University of Hong Kong
Chinese University of Hong Kong
Cairo University
Nanfang Hospital, Southern Medical University
Centre Hospitalier Universitaire de Besancon
Centre Oscar Lambret
University of Aarhus
Assistance Publique - HĂ´pitaux de Paris
Asan Medical Center
Zhejiang University
University of California, Irvine
National Cancer Centre, Singapore
Institute of Oncology Ljubljana
Second Affiliated Hospital, School of Medicine, Zhejiang University
Tata Memorial Centre
University Hospital, Rouen
Nantes University Hospital
Abramson Cancer Center at Penn Medicine
University of California, San Francisco
Eastern Hepatobiliary Surgery Hospital
The University of Hong Kong
Siriraj Hospital
M.D. Anderson Cancer Center
Fudan University
The University of Hong Kong
Third Affiliated Hospital, Sun Yat-Sen University
Mayo Clinic
Sun Yat-sen University
Nantes University Hospital
Tongji Hospital
Sun Yat-sen University
Yonsei University
Sir Run Run Shaw Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Medical University of Warsaw
Shengjing Hospital
City of Hope Medical Center